In the News

After 3-year stumble, new weight-loss drug wins FDA approval

by Traci Bratton

September 12, 2014
Print
Email

From Clinical Endocrinology News
The extended release tablets (Contrave; Orexigen and Takeda) are approved for use in adults who have a body mass index of at least 30 kg/m2, or those with a BMI of at least 27 kg/m2 and at least one additional weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. The agency recommended that Contrave be used in addition to caloric restriction and increased physical activity.

http://www.clinicalendocrinologynews.com/single-article/after-3-year-stumble-new-weight-loss-drug-wins-fda-approval/328669167234813563771f3625619450.html

back to top

Media Policy Guidelines

Marketing and Communications

UAB Home

The University of Alabama at Birmingham

1720 2nd Ave South

Birmingham, AL 35294

Public Relations: (205) 934-3884

Media Specialist On Call: (205) 934-3411

Contact UAB
|
|
A-Z Site Index
|
Privacy
|
Terms of Use
|

UAB is an Equal Employment/Equal Educational Opportunity Institution dedicated to providing equal opportunities and equal access to all individuals regardless of race, color, religion, ethnic or national origin, sex (including pregnancy), genetic information, age, disability, religion, sexual orientation, gender identity, gender expression, and veteran’s status. As required by Title IX, UAB prohibits sex discrimination in any education program or activity that it operates. Individuals may report concerns or questions to UAB’s Assistant Vice President and Senior Title IX Coordinator. The Title IX notice of nondiscrimination is located at uab.edu/titleix.